BEIGENE (688235.SH) reported a revenue of 8.048 billion yuan in the first quarter, a year-on-year increase of 50.2%.
BEIGENE (688235.SH) released the first quarter report for 2025, with the company's revenue in the first quarter being 80....
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
Hong Kong stocks movement | BEIGENE (06160) opened nearly 7% higher as the second indication for the BCL2 inhibitor, lotocilimab, was accepted for listing in China.
BEIGENE (06160) opened nearly 7% higher, and as of the time of writing, it has risen by 6.89%, trading at 136.6 Hong Kong dollars, with a transaction value of 58.3555 million Hong Kong dollars.
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs
BEIGENE (06160) issued 2.0648 million ordinary shares on May 9 due to the exercise of stock options.
BEIGENE (06160) announced that on May 9, 2025, it will issue 206 ordinary shares due to the exercise of stock options...
Results: BeiGene, Ltd. Confounded Analyst Expectations With A Surprise Profit
